Literature DB >> 16087248

Determining genetic stabilities of chimeric dengue vaccine candidates based on dengue 2 PDK-53 virus by sequencing and quantitative TaqMAMA.

Siritorn Butrapet1, Richard M Kinney, Claire Y-H Huang.   

Abstract

The genetic stabilities of the three attenuation loci of the candidate dengue 2 (D2) PDK-53 vaccine virus were evaluated for the PDK-53 virus and PDK-53-vectored chimeric D2/1, D2/3, and D2/4 viruses following 10 sequential passages in Vero cells. Sequencing revealed that the dominant NS1-53-Asp and the NS3-250-Val attenuation loci were extremely stable, whereas reversion occurred at the 5'NCR-57-U locus in 10 of the 18 viral lineages tested. A more sensitive and quantitative assay, the TaqMan mismatch amplification mutation assay (TaqMAMA), was employed to more finely discriminate the level of reversion at the 5'NCR-57 locus. This rapid genetic assay permitted detection of <or=1% reversion of 5'NCR-57 U-to-C in viral populations. By TaqMAMA, various levels of reversion at 5'NCR-57 were detected in all 18 of the PDK-53-based viral lineages tested at Vero passage 10, but only 3 lineages had reversion levels>80% in the viral population. Chimeric viruses based on the PDK-53-V (all three mutations present) genetic background were more stable than those developed in the PDK-53-E (5'NCR and NS1 mutations present) background. The TaqMAMA can be applied in quality control analyses to ensure that attenuated vaccine seeds contain undetectable or minimal levels of reversion at a given attenuation locus.

Mesh:

Substances:

Year:  2005        PMID: 16087248     DOI: 10.1016/j.jviromet.2005.06.019

Source DB:  PubMed          Journal:  J Virol Methods        ISSN: 0166-0934            Impact factor:   2.014


  16 in total

1.  Efficacy of a tetravalent chimeric dengue vaccine (DENVax) in Cynomolgus macaques.

Authors:  Jorge E Osorio; Joseph N Brewoo; Shawn J Silengo; John Arguello; Ioana R Moldovan; Magdalena Tary-Lehmann; Tim D Powell; Jill A Livengood; Richard M Kinney; Claire Y-H Huang; Dan T Stinchcomb
Journal:  Am J Trop Med Hyg       Date:  2011-06       Impact factor: 2.345

2.  Dengue Vaccine: The Current Status.

Authors:  M S Mustafa; V K Agrawal
Journal:  Med J Armed Forces India       Date:  2011-07-21

3.  Safety and Immunogenicity of a Live Attenuated Tetravalent Dengue Vaccine Candidate in Flavivirus-Naive Adults: A Randomized, Double-Blinded Phase 1 Clinical Trial.

Authors:  Sarah L George; Mimi A Wong; Tina J T Dube; Karen L Boroughs; Janae L Stovall; Betty E Luy; Aurelia A Haller; Jorge E Osorio; Linda M Eggemeyer; Sharon Irby-Moore; Sharon E Frey; Claire Y-H Huang; Dan T Stinchcomb
Journal:  J Infect Dis       Date:  2015-03-19       Impact factor: 5.226

Review 4.  Development of DENVax: a chimeric dengue-2 PDK-53-based tetravalent vaccine for protection against dengue fever.

Authors:  Jorge E Osorio; Claire Y-H Huang; Richard M Kinney; Dan T Stinchcomb
Journal:  Vaccine       Date:  2011-07-21       Impact factor: 3.641

5.  Evolution of attenuating mutations in dengue-2 strain S16803 PDK50 vaccine and comparison of growth kinetics with parent virus.

Authors:  Eileen P Kelly; Stephanie Polo; Wellington Sun; Barry Falgout
Journal:  Virus Genes       Date:  2011-04-03       Impact factor: 2.198

6.  Characterization of recombinant dengue-2 virus derived from a single nucleotide substitution in the 5' noncoding region.

Authors:  Vijittra Leardkamolkarn; Wipawan Sirigulpanit; Richard M Kinney
Journal:  J Biomed Biotechnol       Date:  2010-03-22

7.  Molecular determinants of dengue virus 2 envelope protein important for virus entry in FcγRIIA-mediated antibody-dependent enhancement of infection.

Authors:  Nunya Chotiwan; John T Roehrig; Jacob J Schlesinger; Carol D Blair; Claire Y-H Huang
Journal:  Virology       Date:  2014-04-18       Impact factor: 3.616

8.  Dengue type four viruses with E-Glu345Lys adaptive mutation from MRC-5 cells induce low viremia but elicit potent neutralizing antibodies in rhesus monkeys.

Authors:  Hsiao-Han Lin; Hsiang-Chi Lee; Xiao-Feng Li; Meng-Ju Tsai; Hung-Ju Hsiao; Jia-Guan Peng; Shih-Che Sue; Cheng-Feng Qin; Suh-Chin Wu
Journal:  PLoS One       Date:  2014-06-24       Impact factor: 3.240

9.  Modified H5 promoter improves stability of insert genes while maintaining immunogenicity during extended passage of genetically engineered MVA vaccines.

Authors:  Zhongde Wang; Joy Martinez; Wendi Zhou; Corinna La Rosa; Tumul Srivastava; Anindya Dasgupta; Ravindra Rawal; Zhongqui Li; William J Britt; Don Diamond
Journal:  Vaccine       Date:  2009-12-05       Impact factor: 3.641

10.  Genetic and phenotypic characterization of manufacturing seeds for a tetravalent dengue vaccine (DENVax).

Authors:  Claire Y-H Huang; Richard M Kinney; Jill A Livengood; Bethany Bolling; John J Arguello; Betty E Luy; Shawn J Silengo; Karen L Boroughs; Janae L Stovall; Akundi P Kalanidhi; Aaron C Brault; Jorge E Osorio; Dan T Stinchcomb
Journal:  PLoS Negl Trop Dis       Date:  2013-05-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.